Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint
SUZHOU, China, July 25, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line results. Results indicated that the Phase II Stage has reached its primary endpoint with statistically...
Tigermed Completes Acquisition of Japanese CRO Micron
HANGZHOU, China and TOKYO, July 29, 2025 /PRNewswire/ -- Tigermed (300347.SZ / 3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, today announces the completion of its acquisition of CRO company Micron,Inc. Founded in 2005 and headquartered in Tokyo, Micron is a Japan-based Contract Research...
CHICAGO RIVER SWIM APPROVED FOR HISTORIC RETURN THIS SEPTEMBER
First Organized Swim in Nearly a Century will Raise Funds for ALS Research and Youth Swimming Lessons WHAT: Open Water Swim in the Main Stem of the Chicago RiverWHEN: September 21, 2025 | 7:00AM – 10:00AMWEBSITE: ChicagoRiverSwim.org CHICAGO, Aug. 7, 2025 /PRNewswire/ -- The City of Chicago has officially approved the 2025 Chicago River...
VivaVision Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology
WENZHOU, China, Aug. 13, 2025 /PRNewswire/ -- Recently, VivaVision Biotech (Zhejiang) Co., Ltd. (VivaVision) announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board. Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, is currently a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine; he is also a professor...
Mabwell’s CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
SHANGHAI, Aug. 19, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the U.S. Food and Drug Administration (FDA). The clearance enables the initiation of Phase I/II study of 7MW4911 to evaluate the safety, pharmacokinetics, and efficacy in patients with advanced colorectal...
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR) Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions INCHEON,...
Patricia Industries’ subsidiary Advanced Instruments to acquire and merge with Nova Biomedical
NORWOOD, Mass., March 19, 2025 /PRNewswire/ -- Patricia Industries' subsidiary Advanced Instruments, a manufacturer of analytical instruments for the biopharmaceutical and clinical markets, today announced the execution of a definitive agreement to acquire Nova Biomedical, a manufacturer of innovative analytical instruments and consumables that are vital in guiding the treatment of patients...
USANA Philippines Named Among Most Trusted Brands by Reader’s Digest
Second consecutive year USANA won gold award in Natural Food Supplements category MANILA, Philippines, April 24, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, announced today that its Philippines market recently received the gold award in the Natural Food Supplements category at the Reader's Digest Trusted Brands...
Everest Medicines Announces New Drug Application Approval of VELSIPITY® for Adults with Moderately to Severely Active Ulcerative Colitis in Hong Kong
SHANGHAI, April 30, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Department of Health of the Government of the Hong Kong Special Administrative Region, China, has officially approved the New Drug Application (NDA) for VELSIPITY® (etrasimod) for...
Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies
SAN FRANCISCO and SUZHOU, China, May 29, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the first participant has been successfully dosed in a Phase 3 clinical study of picankibart...
